Board of Directors

Board of Directors

Daniela Bosshardt-Hengartner

  • Born 1972, Swiss citizen
  • Pharmacist, Federal Diploma in Pharmacy, Federal Institute of Technology, Zurich
  • Financial analyst at Bank am Bellevue (1998–2002) and M2 Capital (2003–2004)
  • Management consultant in the pharmaceutical, medical technology and biotechnology sectors since 2004
  • Member of the Board of Directors of RepRisk AG (Zurich)

Prof. Dr. Michel Burnier

  • Born 1953, Swiss citizen
  • Swiss-registered Doctor of Internal Medicine and Nephrology
  • University Lecturer, University of Lausanne
  • Formerly a member of the Medicines Committee of the Swiss Association of Pharmacists (until 2001), the Board of Swissmedic (2002–2010) and the Board of Directors of Speedel Holding Ltd. (2007–2009)
  • Member of the following organisations: Swiss Society of Nephrology (former President), Scientific Council of the European Society of Hypertension (Treasurer) and Swiss Society of Hypertension (former President)

Dr. Romeo Cerutti

  • Born 1962, Swiss and Italian citizen
  • Doctor of Law, Law studies at the University of Fribourg, Switzerland; Master of Laws from the University of California, School of Law, Los Angeles
  • Attorney-at-law with Latham and Watkins (1993–1995) and Homburger Rechtsanwälte (1995–1999)
  • Head of Corporate Finance at Lombard Odier Darier Hentsch & Cie (1999–2006) and partner of the Group Holding of Lombard Odier Darier Hentsch & Cie (2004–2006)
  • General Counsel of the Private Banking division Credit Suisse (2006–2009)
  • General Counsel and a member of the Executive Board of Credit Suisse Group Ltd. and Credit Suisse Ltd. since April 2009
  • Member of the Board of Trustees of the University of Fribourg since 2006

Marc de Garidel

  • Born 1958, French citizen
  • Master in Engineering, Ecole Supérieure des Travaux Publics, Paris; Master in International Management, Thunderbird School of Management, Phoenix (USA); Executive Master in Business Administration, Harvard University, Boston (USA)
  • Various positions at Lilly, most recently as finance director Germany (1983–1995)
  • Various positions at Amgen, including Vice-President Finance and Administration Europe, Vice-President and Chief Administration Officer, and General Manager for France and Vice-President of the South International Region (1995–2010)
  • Since 2010 Chairman of the Board of Directors and CEO of Ipsen

Dr. Sylvie Grégoire

  • Born 1961, Canadian and US citizen
  • Dr. pharm., State University of New York in Buffalo (NY/USA), pharmacy degree from Université Laval, Quebec City (Canada)
  • Formerly President of Shire Human Genetic Therapies (2007–2013), worked in various roles at companies including Merck & Company (1987–1995), Biogen Inc. (1995–2003), GlycoFi Inc. (2004–2005) and IDM Pharma (2006–2007)
  • Advisor to venture capital and biotech companies
  • Former member of the Boards of Directors of various companies in the USA and Canada, and the boards of various charitable organisations
  • Member of the Board of Directors of Novo Nordisk and PerkinElmer Inc.

Fritz Hirsbrunner

  • Born 1949, Swiss citizen
  • Lic. oec., HEC University of Lausanne/Senior Executive Program, IMD, Lausanne
  • 1972–1977 Controller at Ciba-Geigy
  • Joined the Galenica Group in 1977 as Assistant to the Corporate Executive Committee; member of the Corporate Executive Committee from 1992 to 2011; Deputy CEO and CFO; Head Investor Relations until February 2014
  • Member of the Board of Directors of Berlac AG, Sissach, and IVF Hartmann Holding AG, Neuhausen
  • Member of the Board of Trustees of IST Investmentstiftung für Personalvorsorge, Zurich
  • Member of the Board of Directors of VenCap 6 Ltd., Jersey

Dr. Gianni Zampieri

  • Swiss citizen
  • PhD ETH Zurich (Federal Institute of Technology), postgraduate study economics, Senior Executive Program, Stanford University, USA
  • Held positions with Hofmann-La Roche and Novartis (Strategic Planning)
  • Joined Vifor Pharma in 1996 as CEO Vifor (International) Ltd., then became Head of the Pharma Division, Galenica Group; 2002 - 2017 Member of the Corporate Executive Committee, 2008 Head of Industrial Operations Vifor Pharma and in 2010 CEO of OM Pharma, 2011 Deputy CEO of Vifor Pharma, 2012 – 2016 Deputy CEO & Head of Pharma Operations
  • May 2016 - May 2017 CEO Vifor Pharma

Daniela Bosshardt-Hengartner

  • Born 1972, Swiss citizen
  • Pharmacist, Federal Diploma in Pharmacy, Federal Institute of Technology, Zurich
  • Financial analyst at Bank am Bellevue (1998–2002) and M2 Capital (2003–2004)
  • Management consultant in the pharmaceutical, medical technology and biotechnology sectors since 2004
  • Member of the Board of Directors of RepRisk AG (Zurich)

Prof. Dr. Michel Burnier

  • Born 1953, Swiss citizen
  • Swiss-registered Doctor of Internal Medicine and Nephrology
  • University Lecturer, University of Lausanne
  • Formerly a member of the Medicines Committee of the Swiss Association of Pharmacists (until 2001), the Board of Swissmedic (2002–2010) and the Board of Directors of Speedel Holding Ltd. (2007–2009)
  • Member of the following organisations: Swiss Society of Nephrology (former President), Scientific Council of the European Society of Hypertension (Treasurer) and Swiss Society of Hypertension (former President)

Dr. Romeo Cerutti

  • Born 1962, Swiss and Italian citizen
  • Doctor of Law, Law studies at the University of Fribourg, Switzerland; Master of Laws from the University of California, School of Law, Los Angeles
  • Attorney-at-law with Latham and Watkins (1993–1995) and Homburger Rechtsanwälte (1995–1999)
  • Head of Corporate Finance at Lombard Odier Darier Hentsch & Cie (1999–2006) and partner of the Group Holding of Lombard Odier Darier Hentsch & Cie (2004–2006)
  • General Counsel of the Private Banking division Credit Suisse (2006–2009)
  • General Counsel and a member of the Executive Board of Credit Suisse Group Ltd. and Credit Suisse Ltd. since April 2009
  • Member of the Board of Trustees of the University of Fribourg since 2006

Marc de Garidel

  • Born 1958, French citizen
  • Master in Engineering, Ecole Supérieure des Travaux Publics, Paris; Master in International Management, Thunderbird School of Management, Phoenix (USA); Executive Master in Business Administration, Harvard University, Boston (USA)
  • Various positions at Lilly, most recently as finance director Germany (1983–1995)
  • Various positions at Amgen, including Vice-President Finance and Administration Europe, Vice-President and Chief Administration Officer, and General Manager for France and Vice-President of the South International Region (1995–2010)
  • Since 2010 Chairman of the Board of Directors and CEO of Ipsen

Dr. Sylvie Grégoire

  • Born 1961, Canadian and US citizen
  • Dr. pharm., State University of New York in Buffalo (NY/USA), pharmacy degree from Université Laval, Quebec City (Canada)
  • Formerly President of Shire Human Genetic Therapies (2007–2013), worked in various roles at companies including Merck & Company (1987–1995), Biogen Inc. (1995–2003), GlycoFi Inc. (2004–2005) and IDM Pharma (2006–2007)
  • Advisor to venture capital and biotech companies
  • Former member of the Boards of Directors of various companies in the USA and Canada, and the boards of various charitable organisations
  • Member of the Board of Directors of Novo Nordisk and PerkinElmer Inc.

Fritz Hirsbrunner

  • Born 1949, Swiss citizen
  • Lic. oec., HEC University of Lausanne/Senior Executive Program, IMD, Lausanne
  • 1972–1977 Controller at Ciba-Geigy
  • Joined the Galenica Group in 1977 as Assistant to the Corporate Executive Committee; member of the Corporate Executive Committee from 1992 to 2011; Deputy CEO and CFO; Head Investor Relations until February 2014
  • Member of the Board of Directors of Berlac AG, Sissach, and IVF Hartmann Holding AG, Neuhausen
  • Member of the Board of Trustees of IST Investmentstiftung für Personalvorsorge, Zurich
  • Member of the Board of Directors of VenCap 6 Ltd., Jersey

Dr. Gianni Zampieri

  • Swiss citizen
  • PhD ETH Zurich (Federal Institute of Technology), postgraduate study economics, Senior Executive Program, Stanford University, USA
  • Held positions with Hofmann-La Roche and Novartis (Strategic Planning)
  • Joined Vifor Pharma in 1996 as CEO Vifor (International) Ltd., then became Head of the Pharma Division, Galenica Group; 2002 - 2017 Member of the Corporate Executive Committee, 2008 Head of Industrial Operations Vifor Pharma and in 2010 CEO of OM Pharma, 2011 Deputy CEO of Vifor Pharma, 2012 – 2016 Deputy CEO & Head of Pharma Operations
  • May 2016 - May 2017 CEO Vifor Pharma